Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | RXRA | P19793 | 1/20 | 0.46 |
| ▸ | RXRB | P28702 | 1/20 | 0.46 |
| ▸ | RXRG | P48443 | 1/20 | 0.46 |
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.46 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.45 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | PPARD | Q03181 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.44 |
| ▸ | SRPK3 | Q9UPE1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5628371 | 0.89 | LRRK2 (0.58) | MAOBRXRARXRBRXRGLRRK2 | |
| SCHEMBL5465981 | 0.87 | LRRK2 (0.55) | RXRARXRBRXRGLRRK2PPARG | |
| SCHEMBL5629550 | 0.83 | LRRK2 (0.55) | MAOBPTGDR2LRRK2MTNR1AMTNR1B | |
| SCHEMBL5627949 | 0.83 | MRGPRX4 (0.48) | MAOBMTNR1AMTNR1BFFAR1MRGPRX4 | |
| SCHEMBL5629957 | 0.80 | MTNR1A (0.45) | MTNR1AMTNR1BFFAR1 | |
| SCHEMBL5628637 | 0.80 | NPC1 (0.48) | RXRAMTNR1AMTNR1BFFAR1 | |
| SCHEMBL5468595 | 0.77 | MAOB (0.46) | MAOBLRRK2FFAR1FFAR2FFAR4 | |
| SCHEMBL5629610 | 0.77 | MAOA (0.53) | MAOBMTNR1AMTNR1BFFAR1MRGPRX4 | |
| SCHEMBL5628095 | 0.76 | FFAR4 (0.50) | MAOBLRRK2FFAR1FFAR4 | |
| SCHEMBL6168319 | 0.76 | CCR5 (0.42) | MAOBMTNR1AMTNR1BMRGPRX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | GLAXO GROUP LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| EP-1509499-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2005-03-02 | — | — | EP | disclosed |
| WO-2003101959-A1 | PYRROLE COMPOUNDS FOR THE TREATMENT OF PROSTAGLANDIN MEDIATED DISEASES | GLAXO GROUP LIMITED (GB) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070082912-A1 | Pyrrole compounds for the treatment of prostaglandine mediated diseases | PTGER1, PTGDR, PTGIR | MAOB 344/4885PTGDR2 5/4885RXRA 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.